Research output per year
Research output per year
Description
This dataset is individual participant data from the CAMERA2 trial.
The dataset contains baseline participant characteristics, details of treatments received, and primary and secondary outcome data. This includes data on mortality, antibiotic treatment, markers for acute kidney injury, microbiologic and serum pathology data and current dialysis, relating to study timepoints at days 5, day 14, 42 and 90.
CAMERA2 - Trial Design:
CAMERA2 was an investigator-initiated, multi-centre, parallel group, open-label, randomised controlled trial powered for superiority, which compared combination antibiotic therapy with standard antibiotic therapy in adults with MRSA bacteraemia.
Consented participants were randomised on day 1 to receive standard therapy alone, or standard therapy plus 7 days of IV β-lactam. Data was captured from randomisation (day 1) until 90 days post randomisation from the participant’s medical records and medication charts (electronic and paper). Whilst the participant remained an inpatient, their medical records were reviewed at least weekly until discharge or the 90 day time point whichever occurred first. Information collected includes blood test results (FBC, EUC, LFTs, CRP, blood cultures and vancomycin levels), relevant comorbidities, baseline SOFA score, baseline PITT bacteraemia, vital status, antibiotic administration, nephrotoxins, echocardiography, MRSA positive cultures and any other hospital admissions if discharged within the 90 days. The attached CRFs (1 to 4) provide data collection specifics.
Blood culture positive bacterial isolates from the index (first positive blood culture taken from this patient for this current hospital admission) through to Day 90 were salvaged from participating sites, please note not all isolates were able to be retrieved. These are also available for use.
Contact person:
Joshua Davis
[email protected]
The dataset contains baseline participant characteristics, details of treatments received, and primary and secondary outcome data. This includes data on mortality, antibiotic treatment, markers for acute kidney injury, microbiologic and serum pathology data and current dialysis, relating to study timepoints at days 5, day 14, 42 and 90.
CAMERA2 - Trial Design:
CAMERA2 was an investigator-initiated, multi-centre, parallel group, open-label, randomised controlled trial powered for superiority, which compared combination antibiotic therapy with standard antibiotic therapy in adults with MRSA bacteraemia.
Consented participants were randomised on day 1 to receive standard therapy alone, or standard therapy plus 7 days of IV β-lactam. Data was captured from randomisation (day 1) until 90 days post randomisation from the participant’s medical records and medication charts (electronic and paper). Whilst the participant remained an inpatient, their medical records were reviewed at least weekly until discharge or the 90 day time point whichever occurred first. Information collected includes blood test results (FBC, EUC, LFTs, CRP, blood cultures and vancomycin levels), relevant comorbidities, baseline SOFA score, baseline PITT bacteraemia, vital status, antibiotic administration, nephrotoxins, echocardiography, MRSA positive cultures and any other hospital admissions if discharged within the 90 days. The attached CRFs (1 to 4) provide data collection specifics.
Blood culture positive bacterial isolates from the index (first positive blood culture taken from this patient for this current hospital admission) through to Day 90 were salvaged from participating sites, please note not all isolates were able to be retrieved. These are also available for use.
Contact person:
Joshua Davis
[email protected]
| Date made available | 2023 |
|---|---|
| Publisher | Menzies School of Health Research |
| Date of data production | Aug 2015 - Jul 2018 |
| Geographical coverage | Global |
Research output
- 1 Article
-
Effect of Vancomycin or Daptomycin with vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients with MRSA Bacteremia: A Randomized Clinical Trial
Tong, S. Y. C., Lye, D. C., Yahav, D., Sud, A., Robinson, J. O., Nelson, J., Archuleta, S., Roberts, M. A., Cass, A., Paterson, D. L., Foo, H., Paul, M., Guy, S. D., Tramontana, A. R., Walls, G. B., McBride, S., Bak, N., Ghosh, N., Rogers, B. A. & Ralph, A. P. & 23 others, , 11 Feb 2020, In: JAMA - Journal of the American Medical Association. 323, 6, p. 527-537 11 p.Research output: Contribution to journal › Article › peer-review
201 Citations (Scopus)